The global radioligand therapy market was valued at USD 2.98 billion in 2025 and is projected to reach USD 15.85 billion by 2035, expanding at a CAGR of 18.2% from 2026, according to SNS Insider. The market is estimated at USD 3.52 billion in 2026, with growth linked to prostate cancer and neuroendocrine tumor demand, wider use of PSMA and SSTR imaging, and increased production of Lutetium-177 and Actinium-225. Pluvicto accounted for about 52.30% of the market in 2025, while prostate cancer represented 58.40% and PSMA-targeted therapies held 61.20%. North America led with an 80.50% share, while Asia Pacific was the fastest-growing region. The report said Novartis received expanded U.S. FDA approval for Pluvicto in earlier-line metastatic castration-resistant prostate cancer in 2026 and began construction of an Indiana manufacturing facility to increase Lutetium-177 output.